Kura Oncology (KURA) Reiterated at Market Outperform by Citizens After Q1 Results

Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).

The analyst commented, "We reiterate our Market Outperform rating and price target of $24 for Kura Oncology based on a discounted EPS and revenue multiple analysis. Yesterday, Kura announced 1Q26 financial results, provided updates on the KOMZIFTI (ziftomenib, zifto) launch and discussed milestones for 2026. Of note, the registrational Phase 3 KOMET-017 trial is enrolling ahead of expectations, with the potential for top-line results for the intensive chemo combo as early as 2028. With signs pointing to a strong KOMZIFTI launch, the frontline AML trials fully funded, the FTI program progressing in the clinic, and a cash position of $580.8MM, we believe Kura shares represent an attractive investment opportunity, with ~59% downside (bear case of $4) and ~200% upside (bull case of $29)."

For an analyst ratings summary and ratings history on Kura Oncology click here. For more ratings news on Kura Oncology click here.

Shares of Kura Oncology closed at $9.68 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• C3.ai (AI) Tops Q4 EPS by 5c, Beats on Revenue; Offers FY27 Revenue Guidance
• Netskope, Inc. (NTSK) Tops Q1 EPS by 1c, Offers Guidance